Press Release
Global Autoinjectors Market to Reach USD 48,029.60 Million by 2035 as GLP-1, Biologics and Self-Administration Reshape Drug Delivery
PRESS RELEASE | Global Data Route Analytics | September 2026
New Global Data Route Analytics study values the market at USD 13,451.97 Million in 2025 and projects a 13.57% CAGR to 2035; North America leads, Asia-Pacific grows fastest at 14.12% CAGR; 151 companies profiled across 15 chapters.
Global Data Route Analytics today announced the publication of Global Autoinjectors Market Size, Share, Trends & Forecast 2020–2035. According to the report, the Global Autoinjectors Market was valued at USD 13,451.97 Million in 2025 and is projected to reach USD 48,029.60 Million by 2035, growing at a CAGR of 13.57%. The market stood at USD 8,420.00 Million in 2020, meaning revenue will have expanded more than five-fold over the fifteen-year study period.
Under 21 CFR 3.2(e), the U.S. FDA classifies a prefilled autoinjector as a single-entity combination product, placing the market at the intersection of pharmaceutical and medical-device regulation. The report treats the category accordingly, quantifying revenue across device reusability, drug-container architecture, nominal capacity, drive mechanism, dose configuration, connectivity, route of administration, therapy area, drug modality, end-use setting and administrator type.
|
Get the sample report with segment-level data tables and the full table of contents:
|
Key Findings
- North America is the largest regional market at USD 6,100.47 Million in 2025, rising to USD 21,813.81 Million by 2035 (13.59% CAGR).
- Europe follows at USD 3,286.32 Million in 2025, reaching USD 11,482.60 Million by 2035.
- Asia-Pacific is the fastest-growing region at a 14.12% CAGR, from USD 2,811.46 Million to USD 10,534.69 Million.
- Single-use / disposable devices hold 97.1% of 2025 revenue; reusable systems grow fastest at 14.69% CAGR.
- Monoclonal antibodies and fusion proteins account for roughly 61% of revenue by drug modality; home and self-care represents about 68% by end-use setting.
Three Forces Driving Growth
First, a compounding chronic-disease base: the IDF Diabetes Atlas counts 589 million adults living with diabetes today, rising to 852.5 million by 2050, while GBD 2021 projects rheumatoid arthritis prevalence to grow 80.2% to 31.7 million by 2050. Second, the GLP-1 wave: the FDA resolved the multi-year semaglutide and tirzepatide shortages only once manufacturers demonstrated national-scale device capacity, and WHO added GLP-1 receptor agonists to its Essential Medicines List in 2025. Third, new therapeutic territory: IV-to-subcutaneous conversion in oncology and a biosimilar pipeline of 90 US-approved products are multiplying autoinjector presentations.
"Device supply, not molecule supply, is increasingly the bottleneck behind GLP-1 availability, and that is reshaping where capital is being deployed across the value chain," said a senior analyst at Global Data Route Analytics.
|
Need country-level, segment-level or company-specific data? Our analysts respond within one business day:
|
Restraints the Report Quantifies
The study also examines high-profile device recalls by the FDA and UK MHRA, pricing scrutiny that runs from the 2016 EpiPen hearings to CMS's negotiated 2027 Medicare price of USD 274 per month for Ozempic against a USD 959 list price, the first needle-free epinephrine nasal spray as a route-of-administration substitute, counterfeit GLP-1 pens entering the legitimate supply chain, and manufacturing-capacity bottlenecks across primary containers, elastomers and assembly.
Companies Profiled
The report profiles 151 companies across 15 chapters, including SHL Medical, Ypsomed, Owen Mumford, Phillips-Medisize, Haselmeier, Nemera, Gerresheimer, Enable Injections, Crossject, Novo Nordisk, Eli Lilly, Sanofi, AbbVie, AstraZeneca, UCB, Teva, Kaleo, ALK-Abelló, Celltrion, Samsung Bioepis, Fresenius Kabi, West Pharmaceutical Services, BD, SCHOTT Pharma, Nipro, Terumo, Recipharm, Catalent, Vetter Pharma and Kindeva Drug Delivery. Recent developments tracked include SHL Medical's USD 220 million South Carolina facility, embecta's acquisition of Owen Mumford, FDA approval of AstraZeneca's Saphnelo Pen and Kindeva's contract worth up to USD 129 million to supply DuoDote autoinjectors to the U.S. Strategic National Stockpile.
|
Buy the full report at a special introductory price:
|
About the Report
The 1,750-page study quantifies the Global Autoinjectors Market across twelve segmentation axes, five regions and 31 countries, includes a dedicated ten-dimension price-analysis chapter and profiles 151 companies across 15 chapters covering device manufacturers, platform and injection-technology companies, pharma users, biosimilar and specialty-injectable companies, connected-device, CDMO, primary-container, safety-syringe, automation and regional emerging-market companies. Deliverables include a 700+ table PDF and an Excel data pack with verified company and product links.
About Global Data Route Analytics
Global Data Route Analytics is a market research and consulting firm delivering syndicated and custom research across healthcare, life sciences, medical devices and adjacent industries. Our reports combine primary interviews, verified secondary sources and proprietary estimation models to give manufacturers, investors and policy teams a quantified basis for decisions.
Report: Global Autoinjectors Market Size, Share, Trends & Forecast 2020–2035
Media & Sales Contact: Global Data Route Analytics | globaldatarouteanalytics.com/contact